The Health Pulse S3E12: From radical to routine: The use of Bayesian statistics in clinical trials

More than a decade ago, Bruno Boulanger made a big bet on applying Bayesian statistics in clinical trials. At the time, very few in the industry thought the method, which applies probabilities to statistical problems, had a place in clinical development. Boulanger saw an opportunity, founding a company that quickly grew and was acquired by CRO PharmaLex in 2018, where he now serves as global head of statistics and data science.In this episode, Boulanger explains how Bayesian statistics uses probability and prediction to solve challenges in the increasingly complex world of clinical research and clinical trial design. Bayesian statistics allows researchers to expand decision making for clinical trials beyond its participants, which is imperative for trials targeting rare diseases. Looking forward, Boulanger is optimistic about the expansion of therapeutic innovation combined with digitalization and data science to meet the unmet needs of patients. All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.